Don't wanna be here? Send us removal request.
Statistics
We looked inside some of the posts by kuickresearch and here's what we found interesting.
Average Info
Notes Per Post
0
Likes Per Post
0
Reblog Per Post
0
Reply Per Post
0
Time Between Posts
8 days ago
Number of Posts By Type
Text
17
Last Seen Tumblr Blogs
Fun Fact
Tumblr has been banned in Indonesia for providing people with access to pornographic content.
Text
Data Entry Services By Kuick Research
Contact: [email protected] or +91-11-47067990
KuicK Research is offering data entry services at reasonable rates to store and utilize your data in a searchable manner. Data entry aids in smarter evaluation of the information by converting useful but complex data into a simple and understandable format. Additionally, outsourcing data entry to KuicK research saves your company’s time and leads to better business decisions leading to a long term feasibility and success of the company.
Outsource data entry and choose KuicK Research as your trusted outsourcing partner. We assure to provide you cost effective data entry services with maximum accuracy in appropriate time. Data entry plays a central role in gathering and representing all the text-based information and business data in a structured form. These efforts result in preventing the risks involved with data sharing and unnecessary hurdles in getting business insights by collecting information of past performances.
With all the knowledge about the significance and methodology of data entry, we’re offering data entry for a wide range of online and offline formats.
Our data entry services include:
v online/offline data entry
v manual data entry
v web data entry
v Ecommerce, image data entry, catalog data entry, PDF data entry
All of the above mentioned services can be further expanded leading to the following list of data entry services provided by our company:
Business card data entry
Index entry
Excel Data Entry
Data entry from handwritten materials
Copying and pasting
Form processing
Data capture
Web Data Entry
Insurance claim entry
Data collection
Questionnaire Data Entry
Sorting and indexing data in any format
Data entry for surveys, credit card application
Other data entry services as per requirements
We are a leading data entry service provider from India offering all types of online and offline data entry services as per your requirements. We have been providing double key data entry (keying is literally done a second time by a different clerk) services for 8 years and widespread our services to clients across USA, Europe, Australia, Canada, Singapore and many more.
0 notes
Text
Peptide Therapeutics Drugs Market Size Clinical Trials Insight 2022
“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market. In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.
“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlights:
Fundamentals of Peptide Therapeutics
Peptide Therapeutics by Applications & Indications
Peptides Clinical Trials Insight by Phase, Indication & Company
Insight on 688 Peptide Drugs in Clinical Trials
Clinical & Patent Insight on 119 Marketed Peptides
Future Peptide Therapeutics Market Outlook
For Report Sample Contact: [email protected]
Or Visit: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Peptide-Therapeutics-Market-%26-Clinical-Trials-Insight-2022
Table of Contents
1. A Revolution of Peptide Therapeutics
1.1 Peptides as Drug Candidates
1.2 Necessity of Peptide Therapeutics
2. Cusp of Small Molecules & Proteins
2.1 Peptides v/s Small Molecules
2.2 Peptides v/s Protein Biologics
3. Fundamentals of Peptide Therapeutics
3.1 Rational Design for Novel Peptides
3.2 Aspects of Regulatory Approvals
4. Peptide Therapeutics by Applications
4.1 Application of Peptides in Imaging
4.2 Application of Peptides in Diseases
5. Peptide Therapeutics in Metabolic Disorder
5.1 Prologue Metabolic Disorders
5.2 Approved Peptide Drugs for Metabolic Disorders
5.3 Market of Metabolic Peptides
6. Peptide Therapeutics in Cancer
6.1 Prologue to Cancer
6.2 Approved Peptide Drugs in Cancer Therapeutics
6.3 Market of Cancer Peptides
7. Peptide Therapeutics in Cardiovascular
7.1 Prologue to Cardiovascular Diseases
7.2 Approved Peptide Drugs in Cardiovascular Diseases
7.3 Market of Cardiac Peptides
8. Peptide Therapeutics in HIV & Infections
8.1 Prologue to Infections
8.2 Approved Peptide Therapeutics in Infections
8.3 Market of Anti-Infectious Peptides
9. Peptide Therapeutics in CNS Disorders
9.1 Prologue to CNS Disorders
9.2 Neuropeptides Drug Delivery to CNS
9.3 Future Market Potential
10. Global Peptide Therapeutics Market
10.1 Prologue to the Peptide Market
10.2 Peptide Market by Application
11. Global Peptide Market by Administration
11.1 Current Trends in Route of Administration
11.2 Current Trends over the Peptide Products
12. Global Peptides Clinical Trials Overview
12.1 Cyclic Peptides
12.2 Depsipeptides
12.3 Dipeptides
12.4 Glucagon-Like Peptides
12.5 Lipopeptides
12.6 Natriuretic Peptides
12.7 Neuropeptides Peptides
12.8 Oligopeptides
12.9 Opioid Peptides
12.10 Peptides
12.11 Peptide Hormones
12.12 Peptide Fragments
12.13 Multiple Peptides
13. Global Peptide Market by Region
13.1 North America
13.2 Europe
13.3 Asia
14. Global Peptide Market Dynamics
14.1 Favorable Parameters
14.2 Challenges
15. Future Peptide Therapeutics Market Outlook
15.1 Future Trends in Peptide Therapeutics
15.2 Future Opportunities of Peptides Therapeutics
16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company
16.1 Research till Preregistration
16.2 Marketed
17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company
17.1 Preclinical till Preregistration
17.2 Marketed
18. Dipeptides Clinical Trials Insight by Phase, Indication & Company
18.1 Preclinical till Registered
18.2 Marketed
19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company
19.1 Preclinical till Phase-I
20. Glucagon-Like Peptides Clinical Trials Insight by Phase, Indication & Company
20.1 Resarch till Phase-III
20.2 Marketed
21. Lipopeptides Clinical Trials Insight by Phase, Indication & Company
21.1 Preclinical till Phase-II
22. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company
22.1 Preclinical till Phase-III
22.2 Marketed
23. Neuropeptides Clinical Trials Insight by Phase, Indication & Company
23.1 Preclinical till Phase-III
23.2 Marketed
24. Oligopeptides Clinical Trials Insight by Phase, Indication & Company
24.1 Preclinical till Registered
24.2 Marketed
25. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company
25.1 Preclinical till Preregistration
25.2 Marketed
26. Peptides Clinical Trials Insight by Phase, Indication & Company
26.1 Research till Registered
26.2 Marketed
27. Peptide Antibiotics Clinical Trials Insight by Phase, Indication & Company
27.1 Research
28. Peptide Aptamers Clinical Trials Insight by Phase, Indication & Company
28.1 Preclinical
29. Peptide Hormones Clinical Trials Insight by Phase, Indication & Company
29.1 Research till Registered
29.2 Marketed
30. Peptide Fragments Clinical Trials Insight by Phase, Indication & Company
30.1 Research till Preregistration
30.2 Marketed
31. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company
31.1 Research till Preregistration
31.2 Marketed
32. Competitive Landscape
32.1 Amgen
32.2 Amylin Pharmaceuticals
32.3 Apitope Technology
32.4 BioPartners
32.5 BiondVax Pharmaceuticals Ltd
32.6 Boehringer Ingelheim
32.7 Circassia
32.8 Corden Pharma (Peptisyntha)
32.9 Eli Lily
32.10 Galena Biopharmaceuticals
32.11 GlaxoSmithKline
32.12 Hyperion Therapeutics
32.13 ImmunoCellular Therapeutics
32.14 Ipsen
32.15 Lonza
32.16 Merck
32.17 NovoNordisk
32.18 Par Pharmaceuticals
32.19 PeptiDream
32.20 Roche
32.21 Sanofi
32.22 Tarix Pharmaceuticals
List of Figures
Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins
Figure 2-2: Layout of Advantages of Peptide Drugs
Figure 3-1: Classification Based over the Sources of Peptide
Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use
Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale
Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs
Figure 3-5: Process of Peptide Therapeutics FDA Approval Path
Figure 4-1: Diagrammatic Representation of the Peptidic Probe
Figure 4-2: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
Figure 5-1: Layout of Metabolic Syndrome Leading to Several Diseases
Figure 5-2: Global - Top 10 Countries with Diabetes Burden (Million), 2030
Figure 5-3: Obesity - Estimated Prevalence by Country (2025)
Figure 5-4: US– GLP-1 Agonist Drugs Cost Comparison (US$)
Figure 5-5: Lantus – Monthly Cost Comparison by Country (US$)
Figure 5-6: Global - Metabolic Disorders Peptide Drug Market (US$ Billion)
Figure 5-7: Victoza - GLP-1 Value Market Percentage Share of Total Diabetic Care Market
Figure 6-1: Global - All Cancer Rates Cases per 100,000 People by Top 10 Country
Figure 6-2: Global - Cancer Peptide Therapeutics Market (US$ Billion), 2014 & 2020
Figure 6 3: Global - Velcade Market Sales (US$ Billion)
Figure 6-4: US – Velcade Sales (US$ Billion), 2016 & 2022
Figure 6-5: Global - Kyprolis Revenues (US$ Billion), 2013 - 2017
Figure 6-6: Global & US - Zoladex Sales (US$ Million), 2016
Figure 7-1: Global & US - Angiomax Sales (US$ Million)
Figure 7-2: Global - Integrilin Sales (US$ Million), 2016
Figure 8-1: Global - Top 10 Leading Causes of Death
Figure 8-2: Global – HIV Prevalence among Varied Regions
Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2016
Figure 9-1: US - Prevalence of Alzheimer’s disease (Millions)
Figure 10-1: Global - Peptide Drug Market (US$ Billion), 2014-2022
Figure 11-1: Therapeutic Peptide Based Drugs over Route of Administration
Figure 12-1: Global – All Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-2: Global - All Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-3: Global - Cyclic Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-4: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 12-5: Global - Depsipeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-6: Global - Depsipeptides Peptides Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-7: Global - Dipeptides Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-8: Global - Dipeptides Peptides Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-9: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-10: Global - Glucagon-Like Peptides Clinical Pipeline by Phase (Number),
2017 till 2022
Figure 12-11: Global - Lipopeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-12: Global - Lipopeptides Peptides Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-13: Global - Natriuretic Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-14: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-15: Global - Neuropeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-16: Global - Neuropeptides Peptides Clinical Pipeline by Phase (Number),
2017 till 2022
Figure 12-17: Global - Oligopeptides Peptides Clinical Pipeline by Phase (%), 2017 till
2022
Figure 12-18: Global - Oligopeptides Peptides Clinical Pipeline by Phase (Number),
2017 till 2022
Figure 12-19: Global - Opioid Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-20: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 12-21: Global - Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-22: Global - Peptides Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 12-23: Global - Peptide Hormones Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-24: Global - Peptide Hormones Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 12-25: Global - Peptide Fragments Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-26: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2017
till 2022
Figure 12-27: Global - Multiple Peptides Clinical Pipeline by Phase (%), 2017 till 2022
Figure 12-28: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2017 till
2022
Figure 14-1: Illustration of Peptide Therapeutics Market Drivers
Figure 14-2: Major Challenges Faced by the Peptide Therapeutics
Figure 15-1: Future Trends of Peptide Therapeutics
sdpriority65 \l\�8N�����
For Report Sample Contact: [email protected]
Or Visit: http://www.pnspharma.com/buy-report.php?reporttitle=Global-Peptide-Therapeutics-Market-%26-Clinical-Trials-Insight-2022
0 notes
Text
CAR T Cell Therapy Market Size Clinical Trials Cost Insight 2022
“Global CAR T Cell Therapy Market & Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.
“Global CAR T Cell Therapy Market & Clinical Trials Insight 2022” report highlights:
CAR T Cell Therapies Delivery Pipeline & Mechanism of Action
Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase
Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies
CAR T Cell Therapies in Highest Phase: Preregistration
Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies
Global Market Scenario of CAR T Cell Therapy
Global CAR T Cell Therapy Market Future Prospects
For Report Sample Contact: [email protected] or +91-11-47067990
Or Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
Table of Contents
1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
1.1 Overview
1.2 History & Development of CAR-T Technology
2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR T Cell
2.2 1nd Generation Chimeric Antigen Receptor
2.3 2nd & 3nd Generation CAR T Cell
3. Principle of Chimeric Antigen Receptor Design
3.1 CAR Modified T Cells: Targeting
3.2 CAR Modified T Cell: Signaling
4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action
4.1 Process of CAR T Cell Therapy
4.2 Mechanism of Action
5. Approaches to Improve the CAR T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR T Cells
5.5 Targeting the Immune Checkpoints
6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors
7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Preregistration
8. Global Market Scenario of CAR T Cell Therapy
8.1 Overview
8.2 Estimated Price Analysis of CAR T Cell Therapy
9. Global Market Size of CAR T Cell Therapy
9.1 Market Share of Cancer Immunotherapy by its Technology
9.2 CAR T Cell Therapy Market Value
10. Global CAR T Cell Therapy Market Dynamics
10.1 Favorable Parameters
10.2 Challenges
11. Global CAR T Cell Therapy Market Future Prospects
12. Competitive Landscape
12.1 Autolus
12.2 Bellicum
12.3 Bluebird
12.4 Celgene
12.5 Cellectis
12.6 Celyad
12.7 Eureka Therapeutics
12.8 Fortress Biotech
12.9 Immune Therapeutics
12.10 Juno Therapeutics
12.11 Kite Pharma
12.12 Novartis
12.13 Sorrento therapeutics
12.14 TILT Biotherapeutics
12.15 Ziopharm
List of Figures
Figure 1-1: Historical Development of CAR T Cell Therapy
Figure 2-1: Structure of Chimeric Antigen Receptor
Figure 2-2: First Generation Chimeric Antigen Receptor
Figure 2-3: Second Generation Chimeric Antigen Receptor
Figure 2-4: Third Generation Chimeric Antigen Receptor
Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T Cell
Figure 4-1: Delivery Pipeline of CAR T Cell Therapy Process
Figure 4-2: CAR T Cell Therapy Mechanism of Action
Figure 5-1: Strategies to Improve CAR T Cell Therapy
Figure 6-1: CAR T Cell Therapy in Brain Tumors
Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
Figure 7-1: Global – CAR T Cell Therapy Clinical Pipeline by Phase (Number), 2017-2022
Figure 7-2: Global – CAR T Cell Therapy Clinical Pipeline by Phase (%), 2017-2022
Figure 8-1: Adoptive T-Cell Therapy - Open Clinical Trials to Investigate the Efficacy & Safety (%), 2015
Figure 8-2: Estimated Cost of T Cell Therapy & CAR T Cell Therapy Per Patient (US$)
Figure 9-1: Cancer Immunotherapy - Market Share of by Its Technology* (%)
Figure 9-2: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
Figure 9-3: Global - Predictive Market of CAR T Cell Therapeutics (US$ Million), 2016-2022
Figure 10-1: Favorable Market Parameters of CAR T Cell Therapy
Figure 10-2: Challenges to Market Growth of CAR T Cell Therapy
Figure 11-1: Future Potential Immuno-Oncology
List of Tables
Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
Table 12-1: Clinical Pipelines of Products
For Report Sample Contact: [email protected] or +91-11-47067990
Or Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
0 notes
Text
CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
Market Opportunity Assessment: More than US$ 60 Billion by 2023
Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
Dosage & Price Analysis on Key Drugs
Mechanism of CD Antigen Cancer Therapeutics
Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
For Report Sample Contact: [email protected] or +91-11-47067990
Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
Table of Contents
1. Introduction to CD Antigen Based Cancer Therapeutics
1.1 Prologue to CD Antigens
1.2 Background: Discovering CD Antigens in Cancer Therapy
1.3 Historical Aspects of CD Antigen Based Cancer Therapeutics
2. Significance of CD Antigens: Normal Cells versus Cancer Cells
2.1 CD Antigens in Normal Cells
2.2 CD Antigens in Cancer
3. Working Mechanism of CD Antigen Based Cancer Therapeutics
4. Commercial Cancer Therapeutics Based on CD Antigens
4.1 Monoclonal Antibodies
4.2 Antibody Drug Conjugates
4.3 Bispecific Antibodies
5. Recent Commercial Trends in CD Antigen Based Cancer Therapeutics
5.1 CAR-T Cell Therapy
5.2 Aptamers
5.3 Immunoconjugates
5.3.1 Radio Immunoconjugate
5.3.2 Toxin Immunoconjugate
5.4 Novel CD Antigen Based Antibodies
5.4.1 Bispecific T-Cell Engager Antibody (BiTEs)
5.4.2 DART and TandAb
6. Major CD Antigens as Targets for Cancer Therapy
6.1 CD20
6.2 CD19
6.3 CD137
6.4 CD38
6.5 CD70
6.6 CD22
6.7 CD30
6.8 CD33
6.9 CD37
7. Major CD Antigens as Cancer Diagnostic Agents
7.1 CD20
7.2 CD5
7.3 CD56
7.4 CD66e
7.5 CD15
7.6 CD30
7.7 CD3
8. Major CD Antigens in Cancer Research
8.1 CD34
8.2 CD10
8.3 CD26
8.4 CD117
8.5 CD44
8.6 CD57
9. Global CD Antigen Based Therapeutics Market Overview
9.1 Market Progression
9.2 Current Market Scenario
9.3 Global CD Antigen Based Cancer Therapeutics Market Trends
9.4 Global Cancer CD Antigen Inhibitors Pipeline Overview
10. Price & Dosage Analysis of Major CD Antigen Based Cancer Therapies
10.1 Rituximab (CD20)
10.2 Ofatumumab (CD20)
10.3 Obinutuzumab (CD20)
10.4 Daratumumab (CD38)
10.5 Brentuximab Vedotin (CD30)
10.6 Gemtuzumab Ozogamicin (CD33)
10.7 Inotuzumab Ozogamicin (CD22)
10.8 Ibritumomab Tiuxetan (CD20)
10.9 Blinatumomab (CD19, CD3)
10.10 Tisagenlecleucel (CD19)
11. Marketed Cancer CD Antigen Inhibitors Clinical & Patent Insight
11.1 Rituximab (MabThera & Rituxan)
11.2 Obinutuzumab (Gazyva & Gazyvaro)
11.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
11.4 Rituximab Biosimilar (AcellBia & USMAL)
11.5 Rituximab Biosimilar (Reditux & Tidecron)
11.6 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)
11.7 Rituximab Biosimilar (Novex)
11.8 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)
11.9 Rituximab Biosimilar (Maball)
11.10 Rituximab Biosimilar (Kikuzubam)
11.11 Rituximab Biosimilar (Mabtas)
11.12 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)
11.13 Avelumab (BAVENCIO)
11.14 Pembrolizumab (Keytruda)
11.15 Atezolizumab (TECENTRIQ)
11.16 Durvalumab (Imfinzi)
11.17 Rituximab Biosimilar (Zytux)
12. Global CD Antigen Cancer Therapy Market Dynamics
12.1 Market Growth Drivers
12.1.1 Large Patient Base
12.1.2 Unmet Medical Need
12.1.3 Better Safety Profile
12.1.4 Accelerated Research & Development: Newly Identified CD Antigens in Cancer
12.1.5 Acquiring Major Share of the Modern Cancer Therapy Market
12.1.6 Strong Clinical Pipeline
12.2 CD Antigen Market Challenges
12.2.1 High Prices of CD Antigen Based Cancer Therapeutics
12.2.2 Difficulties in Differentiating CD Target on Cancer Cells
12.2.3 High Production Cost Due to Complex Structure
13. Global CD Antigens Cancer Therapy Market Future Forecast
14. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Phase-I
15. Cancer CD3 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical
15.2 Phase-I
15.3 Phase-II
16. Cancer CD4 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
16.1 Phase-I
17. Cancer CD7 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical
18. Cancer CD19 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
18.1 Phase-I
18.2 Phase-I/II
18.3 Phase-II
18.4 Phase-III
19. Cancer CD20 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-III
19.9 Registered
20. Cancer CD22 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
20.1 Preclinical
20.2 Phase-III
20.3 Registered
21. Cancer CD 26 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
21.1 Preclinical
21.2 Phase-I/II
22. Cancer CD27 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
22.1 Research
22.2 Preclinical
22.3 Phase-II
23. Cancer CD30 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
23.1 Phase-I
24. Cancer CD33 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
24.1 Phase-I
24.2 Phase-I/II
25. Cancer CD38 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
25.1 Research
25.2 Preclinical
25.3 Phase-I/II
25.4 Phase-III
26. Cancer CD44 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
26.1 Preclinical
26.2 Phase-I
27. Cancer CD45 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
27.1 Phase-III
28. Cancer CD46 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
28.1 Research
29. Cancer CD 47 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II
30. Cancer CD52 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
30.1 Research
30.2 Preclinical
31. Cancer CD55 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical
31.2 Phase-II
32. Cancer CD56 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
32.1 Phase-II
33. Cancer CD66 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
33.1 Phase-I
34. Cancer CD70 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
34.1 Phase-II
35. Cancer CD71 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
35.1 Preclinical
36. Cancer CD98 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
36.1 Phase-I
37. Cancer CD200 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical
37.2 Clinical
37.3 Phase-II
38. Cancer CD223 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical
38.2 Phase-I
38.3 Phase-I/II
38.4 Phase-II
39. Cancer CD248 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
39.1 Preclinical
39.2 Phase-II
40. Cancer CD274 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
40.1 Research
40.2 Preclinical
40.3 Clinical
40.4 Phase-I
40.5 Phase-I/II
41. Cancer CD319 Antigen Inhibitor Clinical Pipeline by Company, Indication & Phase
41.1 Phase-I
42. Cancer Multiple Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Preclinical
42.2 Phase-I
42.3 Phase-I/II
43. Competitive Landscape
43.1 AryoGen Biopharma
43.2 Biocad
43.3 Biogen Idec
43.4 Celltrion
43.5 Genentech
43.6 Genmab
43.7 GLYCART Biotechnology
43.8 Hetero Drugs
43.9 mAbxience
43.10 MedImmune
43.11 Merck
43.12 Sandoz
43.13 UCB
List of Figures
Figure 1-1: Evolution of CD Antigen Based Therapeutic Antibodies in Cancer Therapy
Figure 2-1: CD Antigens as Markers on Normal Leukocytes
Figure 2-2: Significance of CD Antigen in Cancer Cell & its Inhibition by Therapeutic Antibody
Figure 4-1: Types of CD Antigen Based Cancer Therapeutics
Figure 4-2: Structure of Monoclonal Antibody
Figure 4-3: Types of Therapeutic Monoclonal Antibodies
Figure 4-4: Architecture of Antibody Drug Conjugates
Figure 4-5: Bispecific Antibody Structure
Figure 5-1: Advanced CD Antigen Targeting Cancer Therapies
Figure 5-2: Structure of Radio Immunoconjugate
Figure 5-3: Structure of Bispecific T-Cell Engager Antibody
Figure 5-4: Structure of Dual Affinity Re-Targeting Antibody
Figure 6-1: Mechanism of Action of Anti-CD20 Monoclonal Antibody Rituximab
Figure 6-2: Mechanism of Action of Anti-CD30 Antibody Drug Conjugate Brentuximab Vedotin
Figure 9-1: Global - Cancer Therapeutic Monoclonal Antibody Market Share (%), 2017
Figure 9-2: Global - CD20 Cancer Therapeutic Segmentation by Region (%), 2017
Figure 9-3: Global - Rituximab Sales (US$ Billion), 2013-2016
Figure 9-4: Global - Ofatumumab Sales (US$ Million), 2013-2016
Figure 9-5: Global - Obinutuzumab Sales (US$ Million), 2015 & 2016
Figure 9-6: Global - Ibritumomab Tiuxetan Sales (US$ Million), 2013-2016
Figure 9-7: Global - Daratumumab Sales (US$ Million), 2015-2017*
Figure 9-8: Global - Daratumumab Half Yearly Sales (US$ Million), 2016 & 2017
Figure 9-9: Global - Brentuximab Vedotin Sales (US$ Million), 2014-2017
Figure 9-10: Global - Blinatumomab Sales (US$ Million), 2015-2017*
Figure 9-11: Global - Blinatumomab Sales (US$ Million), 2015-2017
Figure 9-12: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-13: Global - Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 9-14: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-15: Global - Cancer CD3 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-16: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-17: Global - Cancer CD19 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-18: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-19: Global - Cancer CD20 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-20: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-21: Global - Cancer CD22 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-22: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-23: Global - Cancer CD26 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-24: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-25: Global - Cancer CD27 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-26: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-27: Global - Cancer CD33 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-28: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-29: Global - Cancer CD38 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-30: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-31: Global - Cancer CD44 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-32: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-33: Global - Cancer CD47 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-34: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-35: Global - Cancer CD52 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-36: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-37: Global - Cancer CD55 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-38: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-39: Global - Cancer CD200 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-40: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-41: Global - Cancer CD223 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-42: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-43: Global - Cancer CD248 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-44: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (%), 2017 till 2023
Figure 9-45: Global - Cancer CD274 Antigen Inhibitor Pipeline by Phase (Number), 2017 till 2023
Figure 9-46: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-47: Global - Cancer CD Multiple Antigen Inhibitors Pipeline by Phase (Number), 2017
Figure 9-48: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (%), 2017 till 2023
Figure 9-49: Global - Cancer CD Total Antigen Inhibitors Pipeline by Phase (Number), 2017 till 2023
Figure 10-1: US - Rituximab Intravenous Solution Price by Concentration (10mg/mL) (US$/Unit), 2017
Figure 10-2: US - Rituximab Vial Price by Quantity (US$), 2017
Figure 10-3: Rituximab Treatment Cost Analysis by Route of Administration (US$), 2017
Figure 10-4: US - Ofatumumab Intravenous Solution Price by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-5: US - Ofatumumab Vial Price by Quantity (US$), 2017
Figure 10-6: Ofatumumab - Treatment Dosage Analysis (mg)
Figure 10-7: Ofatumumab - Price Analysis by Dosage (US$)
Figure 10-8: Obinutuzumab First Cycle Dosage Analysis (mg)
Figure 10-9: Obinutuzumab Treatment Dosage Analysis (mg)
Figure 10-10: US - Obinituzumab Solution Price (US$), 2017
Figure 10-11: Obinutuzumab - Therapy First Cycle Average Cost (US$), 2017
Figure 10-12: Obinutuzumab Average Treatment Cost (US$), 2017
Figure 10-13: Daratumumab Monotherapy Dosage Analysis (mg)
Figure 10-14: Daratumumab Combination Therapy Dosage Analysis (mg)
Figure 10-15: US - Daratumumab Intravenous Solution Cost by Concentration (20mg/mL) (US$/Unit), 2017
Figure 10-16: Daratumumab Vial Price Analysis by Quantity (US$), 2017
Figure 10-17: Daratumumab Monotherapy Average Cost Analysis (US$), 2017
Figure 10-18: Daratumumab Combination Therapy Average Cost Analysis (US$), 2017
Figure 10-19: US - Brentuximab Vedotin Price Analysis, (US$), 2017
Figure 10-20: US - Brentuximab Vedotin Treatment Expenditure (US$), 2014
Figure 10-21: US - Brentuximab Vedotin Treatment Cost (US$), 2017
Figure 10-22: Global - Gemtuzumab Ozogamicin Treatment Cycle Price Analysis (US$), 2010 & 2017
Figure 10-23: US - Ibritumomab Tiuxetan Product & Dose Price Analysis (US$), 2017
Figure 10-24: US - Blinatumomab Dosage Average Price Analysis (US$), 2017
Figure 10-25: US - Blinatumomab Treatment First Cycle Average Cost (US$), 2017
Figure 10-26: US - Blinatumomab Treatment Subsequent Cycle Average Cost (US$), 2017
Figure 12-1: Global CD Antigen Based Cancer Therapy Market Driving Factors
Figure 12-2: Gemtuzumab vs Best Available Therapy Survival Rate
Figure 12-3: Global CD Antigen Based Cancer Therapeutic Market Challenges
List Of Tables
Table 10-1: Rituximab Dosage Indications for Treatment of Different Cancer Conditions
For Report Sample Contact: [email protected] or +91-11-4706799o
Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
0 notes
Text
Download CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report gives comprehensive insight into multiple clinical and non-clinical issues related to emergence and development of global CD Antigen cancer therapy market. CD Antigens have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. CD antigens have been present in disguise since the efforts began to develop therapeutic monoclonal antibodies in 1970s. CD antigens are the basis on which monoclonal antibodies were discovered. Although the potential of antibodies was well understood but it required a series of discoveries to find out that specific antibodies are capable of targeting one unique molecular site of the cancer cells.
“CD Antigen Cancer Therapy Market Outlook & Clinical Trials Insight 2023” report highlights:
Market Opportunity Assessment: More than US$ 60 Billion by 2023
Clinical & Patent Insight on 17 Commercialize CD Antigen Drugs
Clinical & Licensing Insight on 184 CD Antigens in Clinical Pipeline
Dosage & Price Analysis on Key Drugs
Mechanism of CD Antigen Cancer Therapeutics
Cancer CD Antigens Clinical Pipeline Dominated by CD20 Antigen: 50 Drugs
Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
For Report Sample Contact: [email protected] or +91-11-47067990
Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
CD antigens have been used as targets in a wide variety of cancer therapeutics including monoclonal antibodies, antibody-drug-conjugates, tri-functional and bi-specific T-cell engager antibodies, radio immunoconjugates and CAR T-cell therapies. The current scenario clearly indicates that CD Antigens have acquired a major share in the modern cancer therapy market. Approval and commercialization of such a wide variety of cancer therapeutics have shown that continuous efforts have been made to produce unique and improved anti-cancer products.
Global CD antigen based cancer therapy market has evolved since the approval of first CD antigen targeting monoclonal antibody. Current market is fledged with a variety of CD antigen targeting cancer therapies. The market has successfully produced unique CD antigen based cancer therapies. Clinical trials of these therapies have provided evidences that they are better than the existing conventional cancer therapies and provide better quality adjusted life years and prolonged survival to cancer patients.
Although current global CD antigen based cancer therapeutic market is dominated for treating hematological malignancies but strong clinical pipeline having over 100 CD antigen directing cancer drugs consists of various drugs which will be used for treating solid tumors like breast cancer, lung cancer, colorectal cancer, prostate cancer etc. As the number of patients suffering from solid tumors is much higher than the patients suffering from hematological malignancies; an exponential growth can be experienced by Global CD Antigen Cancer Therapy Market after the approval of anti-CD antigenic cancer drugs for treating solid tumors.
The future CD antigen based cancer therapy market is going to be highly competitive as the pharmaceutical companies have to ensure that they are producing unique and more advanced products. Furthermore, CD antigens based cancer therapies has the potential to become popular amongst the patients and physicians as they provide better survival and have justified their high prices in case of some therapies by providing better clinical results than other conventional cancer therapies.
For Report Sample Contact: [email protected] or +91-11-47067990
Visit at : https://www.kuickresearch.com/page-Pharmaceutical%20and%20Healthcare.php
0 notes
Text
Global Cancer Janus Kinase Inhibitors Market Opportunity and Clinical Trial Insight 2023
“Global Cancer Janus Kinase Inhibitors Market Opportunity and Clinical Trial Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters related to development and commercialization of cancer janus kinase inhibitor market. As per report findings, janus kinase inhibitors have emerged as one of the new potential candidate and growth frontier for the various stake holders involved in the research and development of cancer drugs and therapies. At present there is only one janus kinase inhibitors based drug commercially available in the market and 27 drugs are in the various clinical development phases. Most of the drugs are in Preclinical phase (13 Drugs) followed by the Phase-II ( 4 Drugs) clinical trials.
“Global Cancer Janus Kinase Inhibitors Market Opportunity and Clinical Trial Insight 2023” Highlights:
Mechanism of Action of JAK/STAT Inhibitors
Global Cancer JAK/STAT Inhibitor Market Outlook
Global Cancer JAK/STAT Inhibitor Therapy Price Analysis
Global Cancer JAK/STAT Inhibitor Market Dynamics
Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company and Phase
Marketed Cancer Janus Kinase Inhibitors Clinical Insight
Comparative Price Analysis of JAK/STAT Inhibitors and Conventional Cancer Therapies
For Report Sample Contact: [email protected]
Report Weblink:https://www.kuickresearch.com/report-global-cancer-janus-kinase-inhibitors-market-opportunity-and-clinical-trial-insight-2023.php
The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.
JAK/STAT inhibitor being the latest invention in the field of targeted therapies is considered as the best available therapy for cancer by many scientific researchers. JAK/STAT inhibitors target the process involved in the production of the damaged DNA which is playing the major role in developing cancerous cells. The available JAK/STAT inhibitors are highly focused on treating the rare hematological malignancies like myelofibrosis, polycythemia Vera and primary thrombocythemia. However, the continuous efforts of the research community has led to the identification of the role of JAK/STAT pathway in a wide range of tumors including solid tumors like lung cancer, pancreatic cancer, prostate cancer, breast cancer, colorectal cancer, ovarian cancer, gastrointestinal cancers etc.
The global revenue collection from currently available JAK/STAT inhibitor drug; Ruxolitinib, has been very impressive since its approval. Although the drug is approved for treating rare hematological malignancies but incidence rate of these cancers has been found to be increasing in the past five years. Furthermore, the lack of effective treatment for such cancers and increased survival rates of the patients after getting a treatment with Ruxolitinib has aided the commercial success of Ruxolitinib.
More than 5 JAK/STAT inhibitors are expected to enter the cancer therapeutic market in the next decade. The development of JAK/STAT inhibitors has been so impressive and rapid in the past five years that a great economic success of this class of drugs is expected in the nearby future. Additionally, huge commercial success of the JAK inhibitor Ruxolitinib for myeloproliferative disorders has further accelerated the development of more JAK/STAT inhibitors. Advancements in research and technology will aid the development of JAK/STAT inhibitors. The development of more JAK/STAT inhibitors will not only provide benefits to the cancer therapeutic market but will also provide a better life to the patients suffering from cancers.
Past success of JAK/STAT inhibitors has provided an overview of its future market. The clinical success of JAK inhibitor, Ruxolitinib has gained adequate popularity among the patients and the physicians. Due to this reason, the demand of JAK/STAT inhibitors is highly increased. Furthermore, the popularity of Ruxolitinib will aid the market success of other JAK/STAT inhibitory drugs which are going to be licensed very soon.
For Report Sample Contact: [email protected]
Report Weblink:https://www.kuickresearch.com/report-global-cancer-janus-kinase-inhibitors-market-opportunity-and-clinical-trial-insight-2023.php
0 notes
Text
Brazil Wind Power Market Analysis
The wind power sector in Brazil has witnessed tremendous and very fast growth between 2006 and 2011. The cumulative installed capacity for wind power has multiplied by almost six times during 2006-2011. This growth is anticipated to continue in future also with overall installed capacity is estimated to cross 10 GW by 2016. This growth in installed capacity has been due a result of rising awareness in Brazil to switch to green sources of power and a consequent rise in demand for wind power across the nation.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Brazil-Wind-Power-Market-Analysis.php
The Wind farm auctions process followed by the Brazilian government has been the major contributor towards the unprecedented growth of the wind power market in recent years. The auction process adopted by the government has not only contributed in the past growth trajectory attained by wind power market but it has also led to the favorable platform required for the growth levels to be achieved in the future.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Brazil-Wind-Power-Market-Analysis.php
0 notes
Text
India Male Cosmetics Market-Consumer Insight 2012
The Indian cosmetic industry landscape has been witnessing a phenomenal transition from females focused product to male grooming product category. In recent years, male grooming business has emerged as the new growth frontier for cosmetic companies operating in Indian market. The consumption of cosmetics products by Indian male has witnessed upward trend driven by changing lifestyle and increasing rate of urbanization. In India, male consumers are now coming at par with female consumers when it comes to using cosmetics products like fairness cream, anti dark circle cream or even anti wrinkle products.
The consumption of cosmetics products by Indian male has witnessed upward trend in recent years. The Indian male are now coming at par with female consumers when it comes to using cosmetics products like fairness cream, anti dark circle cream or even anti wrinkle products. In our survey results most of the men were found using cosmetic products even if these products are available for female consumers.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Male-Cosmetics-Market-Consumer-Insight-2012.php
The male cosmetics market in India is still in its infancy stage and offers immense opportunity to cosmetics companies which are planning to target male consumers in coming years. The market is yet to be structured and will definitely help the early entrants to get high degree of product acceptability among male consumers. The market is anticipated to witness double digit growth in coming years driven by increasing spending and changing lifestyle among male consumers.
A survey was carried out by KuicK Research to determine the multiple aspects related Male Cosmetics Market in India. The main focus of the survey was to identify and analyze the Spending and Usage pattern across various cosmetics products categories by Male Consumers.
Male Cosmetics Market Survey Sampling
A simple random sampling was used to conduct interviews.
The samples covered for this research were Male consumers aged 15 years to 50 years, from SEC A / B / C households, representing various income groups. They comprised of users of various product categories covered. The samples included students, self employed professionals, working professionals, businessmen.
Samples were selected from the following cities:
Delhi/NCR, Mumbai, Jaipur, Pune, Chandigarh, Lucknow, Bengaluru, Kolkata, Chennai, Bhopal, Amritsar, Ahmedabad, Nagpur, Coimbatore, Kochi, Panaji and Hyderabad
Male Cosmetics Market Survey Methodology
Interviews were conducted in a 2-fold way:
A) Online Interviews - Mails were sent to our panel members, based on their usage habits.
B) Face to Face Interviews – These were also conducted at various purchase points like malls, markets, general stores, cosmetic stores, etc.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Male-Cosmetics-Market-Consumer-Insight-2012.php
0 notes
Text
UAE Power Sector Analysis
UAE is a rapidly growing economy whose electricity sector needs are anticipated to increase upto 50% in order to meet its growing demand for power, by the year 2020. UAE also has one of the highest levels of per capita power consumption across the globe. The electricity consumption in the UAE region is slated to cross 100 TWh by 2012, putting pressure on the supply side. In fact, the power demand is expected to increase at one of the highest rate in the Middle East region till 2020. In 2011, more than 90% of total electricity generated came from thermal based sources in UAE, which is expected to reduce to 90% by 2015. Most of the power in UAE is fuelled by oil and natural gas. At the same time, government is also keen to develop renewable sources of power for future, included investment into nuclear based energy.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-UAE-Power-Sector-Analysis.php
Government’s projections for investment into the UAE power sector are promising. The nation plans to invest more than USD 70 Billion of funds in the sector till around 2015.In fact, till the year 2020, private sector is projected to be presented with an opportunity to invest upto USD 100 Billion into the power generation sector. Some of the prominent players in the UAE energy market are Abu Dhabi Water and Electricity Authority, Dubai Electricity and Water Authority, Sharjah Electricity and Water Authority and Federal Electricity and Water Authority. The seven Emirates in the UAE are catered by these above mentioned four electricity and water authorities.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-UAE-Power-Sector-Analysis.php
0 notes
Text
India Urban And Industrial Waste to Energy Market
The Urban and Industrial waste based power projects have been witnessing upward trend in recent years driven by increasing investments from private sector and ongoing government initiatives to promote generation of power from urban and industrial waste. The overall installed capacity of grid connected waste power projects surpassed 70 MW by end of 2011 as compare to more than 90 MW of off grid waste base power projects.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Urban-And-Industrial-Waste-to-Energy-Market.php
Considering the huge potential to convert waste to energy in India, the Ministry of Environment and Forests had formulated the Municipal Solid Wastes Management and Handling Rules in 2000. Waste to Energy is understood as a renewable technology, and comes under the overall guidance and facilitation of the Ministry of Non Renewable Energy of India, which has announce finacila incentives and assistance programme in. The research report "India Urban & Industrial Waste to Energy Market" gives an overview on the various aspects related to waste based power generation scenario in India. It helps reader to analyze the urban and industrial based power generation potential across various states in India, the current scenario of off grid and grid connected waste based power projects, financial incentives given by government during FY 12 and the key challenges to be resolved for uninterrupted growth of the waste based power generation in India.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Urban-And-Industrial-Waste-to-Energy-Market.php
0 notes
Text
China Healthcare Market Analysis
Healthcare system in China is witnessing series of transformation driven by government backed reform process and increasing private sector participation. Although China healthcare market is fraction of the developed markets, it is actually witnessing double digit growth in recent years. However, within the Chinese healthcare market landscape,there still exists huge difference between the tier one cities and the rural areas. Within the city, there exist huge difference in the level of healthcare services provided by the hospital and small clinics. Chinese healthcare market is very diverse in nature due to presence of multiple hierarchies of healthcare institutions offering services to largest population base in the world. With improvement in the healthcare infrastructure, the Chinese Healthcare Industry is entering into a new era of development. Moreover, increased government spending, has accelerated the development of healthcare infrastructure in China. Large population base having large proportion of ageing people and continuously growing prevalence of lifestyle diseases are further supporting the advancement of the industry. With 1.3 Billion people, China has a huge opportunity in terms of potential patients. However, a closer look at the composition of China s populace reveals a much smaller, although still very large, likely patient pool. Approximately 600 Million people are considered urban residents, while over 700 Million are considered rural residents in China. The rural population is disadvantaged in terms of access to and quality of care. Nevertheless, even without significant uptake in rural patients, China health-care market could continue growing at an intense pace.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-China-Healthcare-Market-Analysis.php
The total healthcare expenditure accounts for only about 5% of the total GDP in China, this percentage has increased over the past few years. Compared with developed countries, this 5% is relatively low. However, with the development of the economy, there is still a great potential for increasing the healthcare expenditure’s percentage of the GDP. “China Healthcare Market Analysis” research report gives detailed overview on the multiple aspects related to healthcare system in China. It helps to understand the recent reform process started by the government and its impact on healthcare market in future. This research report also helps to analyze ongoing trends and the healthcare infrastructure and human resources in China.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-China-Healthcare-Market-Analysis.php
0 notes
Text
Australia Shale Gas Market Analysis
One of the world’s largest natural gas exporters has found a new resource to boost up its profile. While the conventional natural gas reserves seem to be never ending in Australia, it has started tapping its unconventional resources. The world’s largest exporter of coal, Australia, is already a major player in the Coal Seam Gas business and now has found shale gas reserves buried deep under its surface. The fourth largest LNG exporter, Australia might soon become the world’s top most LNG exporter. Australia has 396 Trillion Cubic Feet of recoverable reserves of shale gas spread all over the country. With the shale gas boom engulfing the world right now, Australia does not want to be left behind. It has considerable shale gas reserves that will boost its natural gas exports even further. After the astounding success of shale gas in making US self sufficient in energy, every country is now looking to develop its shale gas reserves and start production as soon as possible. Australia, too, wants to repeat the US shale gas success story but with its own plotline. While, for the US, shale gas proved to be an important tool in cutting its natural gas imports, for Australia, it is a way to get more money by exporting to its largest market, Asia.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Australia-Shale-Gas-Market-Analysis.php
The future of shale gas will largely depend on the assessments that will be done in the next couple of years, which will establish that the estimated reserves as commercially recoverable or not. The investments will be riding on this information and as soon as a positive outlook is presented, companies will rush in to get a share of the shale gas pie in Australia. There is little speculation right now regarding the productivity of these reserves but the international companies are not leaving anything to chance. The shale gas process of exploration and production will, by itself, take at least three to four years to begin production. The future, though, rides on the initial assessment of these shale plays.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Australia-Shale-Gas-Market-Analysis.php
0 notes
Text
Brazil Power Sector Outlook 2016
Brazil, one of the world’s fastest growing economies and the largest power market in South America is moving towards the sustainable development of power sector in future. In the light of its growing power demands, the markets for other sources like natural gas, wind, solar energy are going to expand in addition to the growth of hydro energy, on which most of Brazil’s power depends. Over the coming few years there will be an increase in the inflow of cash for building new transmission and distribution lines and revamping the old ones, presenting a wide variety of opportunities for financial and technical service providers. The Brazilian power segment was privatized in 1997 but even after 15 years the government has an upper hand, which along with many other factors, makes the investors wary.
For Report Sample Contact: [email protected]
Report Weblink:https://www.kuickresearch.com/report-Brazil-Power-Sector-Outlook-2016.php
The whole power scenario of Brazil has come a long way from being a state controlled underinvested sector to a competitive privatized market. The sector which used to be dominated by government policies and regulations, like in any other developing country, has now become an exciting and dynamic open market. The power generation in Brazil is dominated by hydro power which account for more than 70% of the overall installed capacity in recent years. The total installed capacity was around 116 GW by end of 2011, the largest in Latin America and third largest in America region after U.S and Canada. The future of Brazil’s power sector will be focused on generation of power from sources other than hydro. By 2020 the consumption is forecasted to grow by more than 500 TWh and it will require sources like wind, solar, biomass to contribute to the supply. Thus, coming years will see heavy investment, change in government’s policies in favor of these sources and auctions that will be dominated by wind and solar. Apart from developing different sources of power generation there are some issues that need to be tackled by the government which will ensure adequate and fair supply of power to all.
For Report Sample Contact: [email protected]
Report Weblink:https://www.kuickresearch.com/report-Brazil-Power-Sector-Outlook-2016.php
0 notes
Text
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars. They are increasingly partnering with large multinational corporations for clinical trials, regulatory approval processes in the EU/US, and marketing to physicians as well as consumers.
Launching biosimilar products in India also provides firms with an advantage to develop their post-marketing safety and efficacy data. This is specifically significant for biosimilar products as even minor changes in manufacturing processes may lead to serious health issues. One of the key challenges regarding biosimilar products is immunogenicity. Studies that compare innovator biologics and biosimilars often report differences in aggregate levels, protein concentration, stability, conformational states, and impurity profiles. Nevertheless, the biosimilar market is still nascent to gauge which of these differences is significant in determining the safety and efficacy impacts.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Biosimilar-Market-Analysis.php
The Indian biosimilar market includes product segments such as insulin, erythropoietin, GCSF, hormones, interferon alpha, thrombolytics, plasma proteins, vaccines, and others. Of these, insulin is the largest segment of the biosimilar market followed by erythropoietin and GCSF. In 2011, there were about 15 epoetin, 8 G-CSF and 4 insulin biosimilars available in the Indian market. The acceptability of biosimilars is higher in the domestic market. Biosimilar substitution is automatic and can take place as soon as a biosimilar is launched.
“India Biosimilar Market Analysis” research report by KuicK research gives detailed insight on various aspects related the biosimilar market in India like Market Overview, Biosimilar Pipeline Analysis, Biosimilar Development Capabilities of Indian Players, detailed insight into recently announce Guidelines for the Development & Marketing of Biosimilar and competitive landscape.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Biosimilar-Market-Analysis.php
0 notes
Text
Private Hospital Services Market In India
Over the years the share of the private sector in the provision of health care delivery has increased to more than 75% of all outpatient care and about 60% of all in-patient care. The presence of private sector is widespread across the entire Indian healthcare landscape from providing healthcare delivery services, entry of corporate groups in managing and creation of healthcare infrastructure and imparting quality medical education.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Private-Hospital-Services-Market-In-India.php
The private healthcare delivery model is distributed in hospitals, nursing homes (kind of small hospital operated by a doctor or a group of doctors) and outpatient clinics. Indian Hospital Services market is primarily dominated by private players and there are few big players present in the market making it an oligopoly market. Apollo Hospitals Enterprise Ltd (Apollo), MAX Healthcare (MAX), Fortis Healthcare (Fortis), Global Hospitals (Global) and CARE Hospitals (CARE) are some of the leading players in Private Hospital Services market. The Private Hospital Services Market in India is expected to poise a high growth in future backed by increasing demand, favorable government policies and rising investment. Report highlights the expansion in Tier II cities as the next growth frontier for the private hospitals chains operating in India. Research report gives detailed insight on the following aspects related to private hospital market in India:
• India Hospital Services Market Overview • Public & Private Hospital Infrastructure • Human Resource • Investment & Expansion Plans by leading Private Hospital Chain • Demand in Tier II Cities: The New Growth Frontier for Private Hospitals • Emerging Trends • Key Challenges to be Resolved for Uninterrupted Growth • FDI Policy & Regulatory Framework • Competitive LandscapeFor Report Sample Contact: [email protected] Weblink:
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Private-Hospital-Services-Market-In-India.php
0 notes
Text
Japan Solar Power Sector Analysis
Japan has been involved in solar power development since the early 1990s when the country installed its first solar power plant. It has already become one of the top countries for total solar Photo Voltaic (PV) panels installed and its companies are leading manufacturers of PV solar panels. Comparing to the installed generation capacity of Solar PV panels all over the world, Japan stands at the third position after Italy and Germany. Until now, Europe has had a stronghold on the world solar market but Japan, China, USA and Australia are the major economies that are following Europe in the solar footsteps.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Japan-Solar-Power-Sector-Analysis.php
Japan has enormous solar reserves to generate power which can take off the load from fossil fuels and reduce the imports. After the Fukushima nuclear incident there is no nuclear power generation in the country and hence solar energy becomes a frontrunner in sufficing the power demand of the country. With the population still coping with the aftereffects of the disaster and development again taking a faster pace, the country will soon experience a greater need for power for which it will have to diversify its energy sources.
In 2011, the Japan contributed 7% to the world’s total installed solar PV capacity. Japan has grown stronger in terms of installed PV especially after the Fukushima incident which has been supported by a change in the policies as well. Japan started concentrating on solar power generation since the early 1990s; in 2011, it added more than 1 GW in installed capacity for the first time in any given year.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-Japan-Solar-Power-Sector-Analysis.php
0 notes
Text
India Renewable Energy Sector Analysis
Renewable energy contributes substantially to the total power generation capacity in India. In fact in FY’2012, only about 56% of the total electricity produced used coal as the source of fuel to generate electricity, 20% power was produced by hydro or water based sources, 12% electricity was generated using renewable energy sources and gas contributed 9% to the total power generation. while 2% and 1% contribution came from nuclear and diesel based power for the FY’2012.
Indian Government gives multiple benefits to renewable energy projects such as no need for industrial clearance, availability of loan, excise duty exemption, custom duty concession, financial support to renewable energy’s R&D projects, income tax holiday, accelerated depreciation, preferential tariffs, interest and capital subsidies, energy buy-back and third party sale and trading. At the same time, the Government is also trying to reduce the capital cost of renewable energy projects so that more and more companies can invest in the sector. To fulfill this aim, Government is trying to adopt latest and suitable technologies in the sector and promote healthy competition among the players.
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Renewable-Energy-Sector-Analysis.php
Backed by strong policy measures, India has become one of the hottest destinations for investment as it has witnessed more than 60% growth in investment rate. During the year 2011, India has received over US$ 10 Billion of investment showing the fastest expansion in investment trend. Additionally, Introduction of Jawaharlal Nehru Solar Mission (JLNSM) for promotion of solar power is expected to drive huge investment in this field as government has targeted to install 20 GW of solar power by 2020.
Government has set a target to generate 53,000 MW from renewable energy sources by 2017. To achieve this ambitious target government has introduced several programs such as Generation Based Incentives (GBI), Renewable Energy Certificates, Feed-in-Tariff (FIT) support, solar specific, Renewable Purchase Obligation (RPO), Generation Based Incentives (GBI) and long term PPAs.
“India Renewable Energy Sector Analysis” Report gives detailed overview on the following aspect related to renewable energy sector in India:
Significance of renewable energy for India
Installed capacity by various renewable energy resources.
Government support and incentives for promotion of renewable energy by segment.
Current Scenario of decentralize/off grid renewable energy.
New sources of renewable energy: Hydro, Geothermal & Tidal energy.
Detailed policy framework related to renewable energy sector.
Future outlook for renewable energy in India
For Report Sample Contact: [email protected]
Report Weblink: https://www.kuickresearch.com/report-India-Renewable-Energy-Sector-Analysis.php
0 notes